[Antiaggregation activity of arachidonic acid conjugates with neurotropic peptides proglyprol and semax].

Eksperimental'naia i klinicheskaia farmakologiia2014PMID: 25102733

In VitroSemax

Plain Language Summary

Two new derivatives of the peptides Semax and proglyprol — each chemically linked to arachidonic acid — were tested for their ability to reduce platelet clumping. Unlike the parent peptides, both derivatives reduced platelet aggregation triggered by multiple activators in a dose-dependent manner, with the Semax-based derivative showing stronger effects. These compounds may represent a starting point for developing peptide-based antiplatelet drugs.

Abstract

The influence two original derivatives of a therapeutically important peptide, bearing arachidonic acid residue with semax and proglyprol, upon platelet aggregation have been studied in vitro. It is established that both derivatives, in contrast to the parent peptide, possess moderate anti-aggregant properties and produce a dose-dependent decrease in the interplatelet interaction induced by ADP, epinephrine, and arachidonic acid within the concentration range of 0.018 - 1.8 mM. This activity was more pronounced for arachidonoylsemax in comparison with arachidonoylproglyprol.

Authors

Bezuglov, V V; Gretskaia, N M; Vasil'eva, T M; Petrukhina, G N; Andreeva, L A; Miasoedov, N F; Makarov, V A